Nicholas C L Wong
Overview
Explore the profile of Nicholas C L Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong N, Ting H, et al.
Eur J Nucl Med Mol Imaging
. 2024 Jun;
51(11):3485.
PMID: 38900309
No abstract available.
2.
Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong N, Ting H, et al.
Eur J Nucl Med Mol Imaging
. 2020 Nov;
48(5):1371-1389.
PMID: 33179151
Purpose: The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a...
3.
Xing Y, Chand G, Liu C, Cook G, ODoherty J, Zhao L, et al.
J Nucl Med
. 2019 Feb;
60(9):1213-1220.
PMID: 30796165
Immunotherapy with checkpoint inhibitor programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies demonstrates improvements in treatment of advanced non-small cell lung cancer. Treatment stratification depends on immunohistochemical PD-L1 measurement...
4.
Yip C, Cheung P, Wong N, Fung S, Cheung S
Methods Mol Biol
. 2018 Jun;
1806:131-144.
PMID: 29956274
The use of monoclonal antibody (mAb) has become a unique means of targeted therapy for human cancers. mAb-based therapies have shown survival benefits by applying alone or in combination with...
5.
Cheung P, Yip C, Wong N, Fong D, Ng L, Wan A, et al.
Cancer Immunol Res
. 2014 Oct;
2(12):1209-19.
PMID: 25315249
Immunoevasion is an emerging hallmark of cancer. Impairment of natural killer (NK) cytotoxicity is a mechanism to evade host immunosurveillance. Granulin-epithelin precursor (GEP) is a hepatic oncofetal protein regulating growth,...
6.
Wong N, Cheung P, Yip C, Chan K, Ng I, Fan S, et al.
Mol Cancer Ther
. 2014 Sep;
13(12):3001-12.
PMID: 25253787
Granulin-epithelin precursor (GEP) overexpression has been shown in many cancers with functional role on growth, and recently on regulating chemoresistance and cancer stem cell (CSC) properties. Here, we investigate the...
7.
Yip C, Cheung P, Leung I, Wong N, Cheng C, Fan S, et al.
Carcinogenesis
. 2014 Aug;
35(11):2485-94.
PMID: 25115442
Granulin-epithelin precursor (GEP) is a pluripotent secretory growth factor which promotes cancer progression in a number of human cancers. However, how cancer cells interact with GEP remains unknown. In this...
8.
Lam C, Yip C, Poon T, Cheng C, Ng E, Wong N, et al.
PLoS One
. 2012 Jul;
7(7):e40324.
PMID: 22792281
Background And Aim: Granulin-epithelin precursor (GEP) has previously been reported to control cancer growth, invasion, chemo-resistance, and served as novel therapeutic target for cancer treatment. However, the nature and characteristics...
9.
Cheung S, Cheung P, Cheng C, Wong N, Fan S
Gastroenterology
. 2010 Aug;
140(1):344-55.
PMID: 20682318
Background & Aims: Chemotherapy is used to treat unresectable liver cancer with marginal efficacy; this might result from hepatic cancer cells with stem cell and chemoresistant features. Gene expression profiling...